Policy Cures is an independent group providing research, information, decision-making tools and strategic analysis for those involved in the creation of new pharmaceuticals for neglected diseases such as malaria, TB, HIV, pneumonia, sleeping sickness and helminth infections. Our focus is on providing governments, funders and civil society organisations with the information they need to make optimal research and development (R&D) policy and funding decisions for diseases of the developing world.
Building on years of experience in developing world health and public policy, the Policy Cures team have focussed exclusively on neglected disease product development since 2004. Our expertise covers the spectrum of product development from R&D activities and portfolios, to developers, business models, funding, incentives, pricing and access issues.
The team has public and private sector expertise in developing world health, R&D, medicine, economics, international health policy, and international and intellectual property law.
Our cross-disciplinary team and specialist knowledge allow us to develop fresh, innovative solutions to policy questions, moving beyond traditional approaches to ideas that work in today’s changing world.
Policy Cures stakes its reputation on providing neutral, balanced analysis built on in-depth understanding of, and relations with, organisations from all sectors of the R&D spectrum, including government, multilateral, philanthropic, private sector and civil society.
Our expertise and broad network of relationships allow us to assess solutions for their real-world applicability before they are given to clients, including regulatory aspects, scientific and technical feasibility, funding implications and political acceptability.